SEARCH

SEARCH BY CITATION

References

  • Adami, R. (1993) Therapeutic thrombocytapheresis: a review of 132 patients. International Journal of Artificial Organs, 16(Suppl. 5), 183184.
  • Afshar-Kharghan, V.L.A., Gray, L., Padilla, A., Borthakur, G., Roberts, S., Pruthi, R. & Tefferi, A. (2001) Hemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia. Blood, 98, 471a.
  • Amitrano, L., Guardascione, M.A., Ames, P.R., Margaglione, M., Antinolfi, I., Iannaccone, L., Annunziata, M., Ferrara, F., Brancaccio, V. & Balzano, A. (2003) Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. American Journal of Hematology, 72, 7581.
  • Anger, B., Haug, U., Seidler, R. & Heimpel, H. (1989a) Polycythemia vera. A clinical study of 141 patients. Blut, 59, 493500.
  • Anger, B.R., Seifried, E., Scheppach, J. & Heimpel, H. (1989b) Budd–Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klinische Wochenschrift, 67, 818825.
  • Antithrombotic Trialist's Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 7186.
  • Asano, Y. & Okaniwa, A. (1987) In utero morphological effects of hydroxyurea on the fetal development in Sprague–Dawley rats. Jikken Dobutsu, 36, 143149.
  • Baker, R.I. & Manoharan, A. (1988) Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. European Journal of Haematology, 40, 267272.
  • Balduini, C.L., Bertolino, G., Noris, P. & Piletta, G.C. (1991) Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. American Journal of Clinical Pathology, 95, 8286.
  • Barbui, T. & Finazzi, G. (2003) Indications for cytoreductive therapy in polycythemia vera and essential thrombocythemia. Hematology, 2003, 202209.
  • Barbui, T., Cortelazzo, S., Viero, P., Bassan, R., Dini, E. & Semeraro, N. (1983) Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. European Journal of Cancer and Clinical Oncology, 19, 15931599.
  • Barbui, T., Barosi, G., Grossi, A., Gugliotta, L., Liberato, L.N., Marchetti, M., Mazzucconi, M.G., Rodeghiero, F. & Tura, S. (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Experimental Hematology. Haematologica, 89, 215232.
  • Barton, J., Lavker, R.M., Schechter, N.M. & Lazarus, G.S. (1985) Treatment of urticaria pigmentosa with corticosteroids. Archives of Dermatology, 121, 15161523.
  • Bazzan, M., Tamponi, G., Schinco, P., Vaccarino, A., Foli, C., Gallone, G. & Pileri, A. (1999) Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Annals of Hematology, 78, 539543.
  • Beck, Jr M.R., & Eckstein, E.C. (1980) Preliminary report on platelet concentration in capillary tube flows of whole blood. Biorheology, 17, 455464.
  • Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. & Boiron, M. (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer, 58, 24402447.
  • Berk, P.D., Goldberg, J.D., Silverstein, M.N., Weinfeld, A., Donovan, P.B., Ellis, J.T., Landaw, S.A., Laszlo, J., Najean, Y., Pisciotta, A.V. & Wasserman, L.R. (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. New England Journal of Medicine, 304, 441447.
  • Berk, P.D., Goldberg, J.D., Donovan, P.B., Fruchtman, S.M., Berlin, N.I. & Wasserman, L.R. (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23, 132143.
  • Besses, C., Cervantes, F., Pereira, A., Florensa, L., Sole, F., Hernandez-Boluda, J.C., Woessner, S., Sans-Sabrafen, J., Rozman, C. & Montserrat, E. (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia, 13, 150154.
  • Bond, L. & Bevan, D. (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. New England Journal of medicine, 318, 121.
  • Brodmann, S., Passweg, J.R., Gratwohl, A., Tichelli, A. & Skoda, R.C. (2000) Myeloproliferative disorders: complications, survival and causes of death. Annals of Hematology, 79, 312318.
  • Budde, U. & van Genderen, P.J. (1997) Acquired von Willebrand disease in patients with high platelet counts. Seminars in Thrombosis and Hemostasis, 23, 425431.
  • Budde, U., Schaefer, G., Mueller, N., Egli, H., Dent, J., Ruggeri, Z. & Zimmerman, T. (1984) Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood, 64, 981985.
  • Budde, U., Dent, J.A., Berkowitz, S.D., Ruggeri, Z.M. & Zimmerman, T.S. (1986) Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood, 68, 12131217.
  • Budde, U., Scharf, R.E., Franke, P., Hartmann-Budde, K., Dent, J. & Ruggeri, Z.M. (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood, 82, 17491757.
  • Burstein, S.A., Malpass, T.W., Yee, E., Kadin, M., Brigden, M., Adamson, J.W. & Harker, L.A. (1984) Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. British Journal of Haematology, 57, 383392.
  • Buss, D.H., Stuart, J.J. & Lipscomb, G.E. (1985) The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. American Journal of Hematology, 20, 365372.
  • Byrnes, J.J., Larcada, A. & Moake, J.L. (1988) Thrombosis following desmopressin for uremic bleeding. American Journal of Hematology, 28, 6365.
  • Cardin, F., Graffeo, M., McCormick, P.A., McIntyre, N. & Burroughs, A. (1992) Adult ‘‘idiopathic’’ extrahepatic venous thrombosis. Importance of putative ‘‘latent’’ myeloproliferative disorders and comparison with cases with known etiology. Digestive Diseases and Sciences, 37, 335339.
  • Chiusolo, P., La Barbera, E.O., Laurenti, L., Piccirillo, N., Sora, F., Giordano, G., Urbano, R., Mazzucconi, M.G., De Stefano, V., Leone, G. & Sica, S. (2001) Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Experimental Hematology, 29, 670676.
  • Colombi, M., Radaelli, F., Zocchi, L. & Maiolo, A.T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer, 67, 29262930.
  • Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. & Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology, 8, 556562.
  • Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine, 332, 11321136.
  • Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. Blood, 6, 372375.
  • Denninger, M.H., Chait, Y., Casadevall, N., Hillaire, S., Guillin, M.C., Bezeaud, A., Erlinger, S., Briere, J. & Valla, D. (2000) Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology, 31, 587591.
  • Dicato, M.A., Schroell, B. & Berchem, G.J. (1999) V Leiden mutations, prothromin and methylene-tetrahydrofolate reductase are not risk factors for thromboembolic disease in essential thrombocythemia. Blood, 94, 111a
  • Doll, D.C., Ringenberg, Q.S. & Yarbro, J.W. (1989) Antineoplastic agents and pregnancy. Seminars in Oncology, 16, 337346.
  • Elliott, M.A. & Tefferi, A. (1997) Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Seminars in Thrombosis and Hemostasis, 23, 463472.
  • Elliott, M.A. & Tefferi, A. (2003) Thrombocythaemia and pregnancy. Bailliere's Best Practice in Clinical Haematology, 16, 227242.
  • Falanga, A., Marchetti, M., Evangelista, V., Vignoli, A., Licini, M., Balicco, M., Manarini, S., Finazzi, G., Cerletti, C. & Barbui, T. (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 96, 42614266.
  • Faurschou, M., Nielsen, O.J., Jensen, M.K. & Hasselbalch, H.C. (2000) High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. American Journal of Hematology, 65, 136140.
  • Favaloro, E.J. (2000) Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thrombosis and Haemostasis, 83, 127135.
  • Fenaux, P., Simon, M., Caulier, M.T., Lai, J.L., Goudemand, J. & Bauters, F. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer, 66, 549556.
  • Fey, M.F. (1985) Spontaneous massive abdominal wall hematoma in polycythemia vera. Acta Haematologica, 73, 122123.
  • Finazzi, G., Ruggeri, M., Rodeghiero, F. & Barbui, T. (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. [see comment]. British Journal of Haematology, 110, 577583.
  • Furlan, M., Robles, R. & Lamie, B. (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 87, 42234234.
  • Galli, M., Luciani, D., Bertolini, G. & Barbui, T. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 101, 18271832.
  • van Genderen, P.J. & Leenknegt, H. (1999) Normal binding of plasma von Willebrand factor to platelets in essential thrombocythemia. American Journal of Hematology, 61, 153154.
  • van Genderen, P.J. & Michiels, J.J. (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Medicale, 23, 7377.
  • van Genderen, P.J., Michiels, J.J., van der Poel-van de Luytgaar de, S.C. & van Vliet, H.H. (1994) Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Annals in Hematology, 69, 8184.
  • van Genderen, P.J., Michiels, J.J., van Strik, R., Lindemans, J. & van Vliet, H.H. (1995) Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thrombosis and Haemostasis, 73, 210214.
  • van Genderen, P.J., Lucas, I.S., van Strik, R., Vuzevski, V.D., Prins, F.J., van Vliet, H.H. & Michiels, J.J. (1996a) Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thrombosis and Haemostasis, 76, 333338.
  • van Genderen, P.J., Budde, U., Michiels, J.J., van Strik, R. & van Vliet, H.H. (1996b) The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. British Journal of Haematology, 93, 962965.
  • van Genderen, P.J., Leenknegt, H. & Michiels, J.J. (1997a) The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link? Seminars in Thrombosis and Hemostasis, 23, 385389.
  • van Genderen, P.J., Prins, F.J., Lucas, I.S., van de Moesdijk, D., van Vliet, H.H., van Strik, R. & Michiels, J.J. (1997b) Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. British Journal of Haematology, 99, 832836.
  • van Genderen, P.J., van Vliet, H.H., Prins, F.J., de Moesdijk, D., van Strik, R., Zijlstra, F.J., Budde, U. & Michiels, J.J. (1997c) Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Annals of Hematology, 75, 215220.
  • van Genderen, P.J., Mulder, P.G., Waleboer, M., van de Moesdijk, D. & Michiels, J.J. (1997d) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. British Journal of Haematology, 97, 179184.
  • Gersuk, G.M., Carmel, R. & Pattengale, P.K. (1989) Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood, 74, 23302334.
  • Gisslinger, H., Rodeghiero, F., Ruggeri, M., Heis-Vahidi Fard, N., Mannhalter, C., Papagiannopoulos, M., Rintelen, C., Lalouschek, W., Knobl, P., Lechner, K. & Pabinger, I. (1999) Homocysteine levels in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 105, 551555.
  • Greist, A. (2002) The role of blood component removal in essential and reactive thrombocytosis. Therapeutic Apheresis, 6, 3644.
  • Grima, K.M. (2000) Therapeutic apheresis in hematological and oncological diseases. Journal of Clinical Apheresis, 15, 2852.
  • Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Annals of Internal Medicine, 123, 656664.
  • Harrison, C.N., Gale, R.E., Machin, S.J. & Linch, D.C. (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417424.
  • Harrison, C.N., Donohoe, S., Carr, P., Dave, M., Mackie, I. & Machin, S.J. (2002) Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thrombosis and Haemostasis, 87, 802807.
  • Huang, P.Y. & Hellums, J.D. (1993) Aggregation and disaggregation kinetics of human blood platelets: Part III. The disaggregation under shear stress of platelet aggregates. Biophysical Journal, 65, 354361.
  • Ishihara, S., Yasuhara, H., Ogawa, S. & Muto, T. (2000) Successful surgical treatment for spontaneous retroperitoneal hematoma in polycythemia vera: report of a case. Surgery Today, 30, 199201.
  • Jacobson, A.K. (2004) Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Practical Research in Clinical Haematology, 17, 5564.
  • Jantunen, R., Juvonen, E., Ikkala, E., Oksanen, K., Anttila, P. & Ruutu, T. (2001) The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Annals of Hematology, 80, 7478.
  • Jensen, M.K., de Nully Brown, P., Nielsen, O.J. & Hasselbalch, H.C. (2000a) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. European Journal of Haematology, 65, 132139.
  • Jensen, M.K., de Nully Brown, P., Lund, B.V., Nielsen, O.J. & Hasselbalch, H.C. (2000b) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. British Journal of Haematology, 110, 116124.
  • Jensen, M.K., de Nully Brown, P., Lund, B.V., Nielsen, O.J. & Hasselbalch, H.C. (2001) Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. European Journal of Haematology, 66, 143151.
  • Jensen, M.K., de Nully Brown, P., Thorsen, S. & Hasselbalch, H.C. (2002) Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. American Journal of Hematology, 69, 185191.
  • Juvonen, E., Partanen, S. & Ruutu, T. (1987) Colony formation by megakaryocytic progenitors in essential thrombocythaemia. British Journal of Haematology, 66, 161164.
  • Kaplan, M.E., Mack, K., Goldberg, J.D., Donovan, P.B., Berk, P.D. & Wasserman, L.R. (1986) Long-term management of polycythemia vera with hydroxyurea: a progress report. Seminars in Hematology, 23, 167171.
  • El-Kassar, N., Hetet, G., Briere, J. & Grandchamp, B. (1997) Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood, 89, 128134.
  • Kassum, D. & Thomas, E.J. (1977) Morbidity and mortality of incidental splenectomy. Canadian Journal of Surgery, 20, 209214.
  • Kaywin, P., McDonough, M., Insel, P.A. & Shattil, S.J. (1978) Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. New England Journal of Medicine, 299, 505509.
  • Kessler, C.M., Klein, H.G. & Havlik, R.J. (1982) Uncontrolled thrombocytosis in chronic myeloproliferative disorders. British Journal of Haematology, 50, 157167.
  • Key, N.S. & McGlennen, R.C. (2002) Hyperhomocyst(e)inemia and Thrombophilia. Archives of Pathology and Laboratory Medicine, 126, 13671375.
  • Landolfi, R. & Marchioli, R. (1997) European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Seminars in Thrombosis and Hemostasis, 23, 473478.
  • Landolfi, R., Ciabattoni, G., Patrignani, P., Castellana, M.A., Pogliani, E., Bizzi, B. & Patrono, C. (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. [see comment]. Blood, 80, 19651971.
  • Landolfi, R., Rocca, B. & Patrono, C. (1995) Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Critical Reviews in Oncology-Hematology, 20, 203222.
  • Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., Barbui, T. & European Collaboration on Low-Dose Aspirin in Polycythemia Vera, I. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114124.
  • Le Blanc, K., Lindahl, T., Rosendahl, K. & Samuelsson, J. (1998) Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thrombosis Research, 91, 287295.
  • Lengfelder, E., Hochhaus, A., Kronawitter, U., Hoche, D., Queisser, W., Jahn-Eder, M., Burkhardt, R., Reiter, A., Ansari, H. & Hehlmann, R. (1998) Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. British Journal of Haematology, 100, 1523.
  • Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, Jr J.D., Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488494.
  • Lopez-Fernandez, M.F., Lopez-Berges, C., Martin, R., Pardo, A., Ramos, F.J. & Batlle, J. (1987) Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thrombosis and Haemostasis, 58, 753757.
  • Malmaeus, J., Akre, T., Adami, H.O. & Hagberg, H. (1986). Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. British Journal of Surgery, 73, 720723.
  • Mazzucato, M., De Marco, L., De Angelis, V., De Roia, D., Bizzaro, N. & Casonato, A. (1989) Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. British Journal of Haematology, 73, 369374.
  • Melear, J.M., Goldstein, R.M., Levy, M.F., Molmenti, E.P., Cooper, B., Netto, G.J., Klintmalm, G.B. & Stone, M.J. (2002) Hematologic aspects of liver transplantation for Budd–Chiari syndrome with special reference to myeloproliferative disorders. Transplantation, 74, 10901095.
  • Menon, K.V., Shah, V. & Kamath, P.S. (2004) The Budd-Chiari syndrome. [see comment]. New England Journal of Medicine, 350, 578585.
  • Michiels, J.J. (1997) Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism–thesis, Rotterdam, 1981. Seminars in Thrombosis Hemostasis, 23, 335338.
  • Michiels, J.J., Abels, J., Steketee, J., van Vliet, H.H. & Vuzevski, V.D. (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Annals of Internal Medicine, 102, 466471.
  • Michiels, J.J., Koudstaal, P.J., Mulder, A.H. & van Vliet, H.H. (1993) Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology, 43, 11071110.
  • Michiels, J.J., van Genderen, P.J., Jansen, P.H. & Koudstaal, P.J. (1996) Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leukemia and Lymphoma, 22 (Suppl. 1), 6570.
  • Michiels, J.J., Budde, U., van der Planken, M., van Vliet, H.H., Schroyens, W. & Berneman, Z. (2001) Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Bailliere's Best Practice in Clinical Haematology, 14, 401436.
  • Najean, Y., Mugnier, P., Dresch, C. & Rain, J.D. (1987) Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. British Journal of Haematology, 67, 285291.
  • Passamonti, F. (2004) The natural history of PV and ET. American Journal of Medicine (in press).
  • Passamonti, F., Malabarba, L., Orlandi, E., Pascutto, C., Brusamolino, E., Astori, C., Barate, C., Canevari, A., Corso, A., Bernasconi, P., Cazzola, M. & Lazzarino, M. (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. British Journal of Haematology, 116, 855861.
  • Passamonti, F., Malabarba, L., Orlandi, E., Barate, C., Canevari, A., Brusamolino, E., Bonfichi, M., Arcaini, L., Caberlon, S., Pascutto, C. & Lazzarino, M. (2003) Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. [comment]. Haematologica, 88, 1318.
  • Patrono, C., Coller, B., Dalen, J.E., FitzGerald, G.A., Fuster, V., Gent, M., Hirsh, J. & Roth, G. (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest, 119, 39S63S.
  • Pearson, T.C. (1997) Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Seminars in Thrombosis and Hemostasis, 23, 433439.
  • Pearson, T.C. (2002) The risk of thrombosis in essential thrombocythemia and polycythemia vera. Seminars in Oncology, 29, 1621.
  • Pearson, T.C. & Wetherley-Mein, G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 2, 12191222.
  • Perea, G., Remacha, A., Besses, C., Jimenez, M., Florensa, L. & Cervantes, F. (2001) Is polycythemia vera a serious disease in young adults? Haematologica, 86, 543544.
  • Petitt, R.M., Silverstein, M.N. & Petrone, M.E. (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Seminars in Hematology, 34, 5154.
  • Press, R.D., Bauer, K.A., Kujovich, J.L. & Heit, J.A. (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Archives of Pathology and Laboratory Medicine, 126, 13041318.
  • Randi, M.L., Stocco, F., Rossi, C., Tison, T. & Girolami, A. (1991) Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). Journal of Medicine, 22, 213223.
  • Randi, M.L., Rossi, C., Fabris, F., Menapace, L. & Girolami, A. (1999a) Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clinical Applications in Thrombosis and Hemostasis, 5, 131135.
  • Randi, M.L., Luzzatto, G. & Fabris, F. (1999b) Low-risk essential thrombocythaemia in patients younger than 40[comment]. British Journal of Haematology, 104, 929.
  • Randi, M.L., Fabris, F., Ruzzon, E., Pacquola, E., Cella, G. & Girolami, A. (2002). Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Haematologica, 87, 11801184.
  • Regev, A., Stark, P., Blickstein, D. & Lahav, M. (1997) Thrombotic complications in essential thrombocythemia with relatively low platelet counts. American Journal of Hematology, 56, 168172.
  • Remaley, A.T., Kennedy, J.M. & Laposata, M. (1989) Evaluation of the clinical utility of platelet aggregation studies. American Journal of Hematology, 31, 188193.
  • Rocca, B., Ciabattoni, G., Tartaglione, R., Cortelazzo, S., Barbui, T., Patrono, C. & Landolfi, R. (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thrombosis Haemostasis, 74, 12251230.
  • Rosendaal, F.R. (1997) Risk factors for venous thrombosis: prevalence, risk, and interaction. Seminars in Hematology, 34, 171187.
  • Rozman, C., Giralt, M., Feliu, E., Rubio, D. & Cortes, M.T. (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 67, 26582663.
  • Ruggeri, Z.M. (2001) Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Practical Research in Clinical Haematology, 14, 257279.
  • Ruggeri, M., Castaman, G. & Rodeghiero, F. (1993) Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica, 78, 1821.
  • Ruggeri, M., Finazzi, G., Tosetto, A., Riva, S., Rodeghiero, F. & Barbui, T. (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. British Journal of Haematology, 103, 772777.
  • Ruggeri, M., Gisslinger, H., Tosetto, A., Rintelen, C., Mannhalter, C., Pabinger, I., Heis, N., Castaman, G., Missiaglia, E., Lechner, K. & Rodeghiero, F. (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 71, 16.
  • Sadler, J.E., Mannucci, P.M., Berntorp, E., Bochkov, N., Boulyjenkov, V., Ginsburg, D., Meyer, D., Peake, I., Rodeghiero, F. & Srivastava, A. (2000) Impact, diagnosis and treatment of von Willebrand disease. Thrombosis and Haemostasis, 84, 160174.
  • Sato, K. (1988) Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio Journal of Medicine, 37, 5471.
  • Schafer, A.I. (1982) Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. New England Journal of Medicine, 306, 381386.
  • Schafer, A.I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64, 112.
  • Shih, L.Y., Lin, T.L., Lai, C.L., Dunn, P., Wu, J.H., Wang, P.N., Kuo, M.C. & Lee, L.C. (2002) Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood, 100, 15961601.
  • Solberg, Jr L.A., Tefferi, A., Oles, K.J., Tarach, J.S., Petitt, R.M., Forstrom, L.A. & Silverstein, M.N. (1997) The effects of anagrelide on human megakaryocytopoiesis. British Journal of Haematology, 99, 174180.
  • Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia:risks and benefits up to 9 years of treatment. [see comment] [erratum appears in JAMA 2003 August 13; 290 (6), 756]. JAMA, 289, 16451651.
  • Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. & Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. [see Comment]. Blood, 91, 616622.
  • Storen, E.C. & Tefferi, A. (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood, 97, 863866.
  • Tartaglia, A.P., Goldberg, J.D., Berk, P.D. & Wasserman, L.R. (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Seminars in Hematology, 23, 172176.
  • Tefferi, A. (2003) Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings, 78, 174194.
  • Tefferi, A. & Murphy, S. (2001) Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Reviews, 15, 121131.
  • Tefferi, A., Silverstein, M.N., Petitt, R.M., Mesa, R.A. & Solberg, Jr L.A., (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Seminars in Thrombosis and Hemostasis, 23, 379383.
  • Tefferi, A., Mesa, R.A., Nagorney, D.M., Schroeder, G. & Silverstein, M.N. (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single- institution experience with 223 patients. Blood, 95, 22262233.
  • Tefferi, A., Fonseca, R., Pereira, D.L. & Hoagland, H.C. (2001) A long-term retrospective study of young women with essential thrombocythemia. Mayo Clinical Proceedings, 76, 2228.
  • Tsai, H.M. (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 42354244.
  • Turitto, V.T. & Weiss, H.J. (1983) Platelet and red cell involvement in mural thrombogenesis. Annals of the New York Academy of Sciences, 416, 363376.
  • Ushikubi, F., Okuma, M., Ishibashi, T., Narumiya, S. & Uchino, H. (1990) Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. American Journal of Hematology, 33, 96100.
  • Valla, D., Casadevall, N., Lacombe, C., Varet, B., Goldwasser, E., Franco, D., Maillard, J.N., Pariente, E.A., Leporrier, M. & Rueff, B. (1985) Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Annals of Internal Medicine, 103, 329334.
  • Van Cott, E.M., Laposata, M. & Prins, M.H. (2002) Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Archives of Pathology and Laboratory Medicine, 126, 12811295.
  • Wade, J.P., Pearson, T.C., Russell, R.W. & Wetherley-Mein, G. (1981) Cerebral blood flow and blood viscosity in patients with polycythaemia secondary to hypoxic lung disease. British Medical Journal (Clinical Research Edition), 283, 689692.
  • Warkentin, T.E., Roberts, R.S., Hirsh, J. & Kelton, K.G. (2003). An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine, 163, 25182524.
  • Watson, K.V. & Key, N. (1993) Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. British Journal of Haematology, 83, 198203.
  • Waysbort, A., Giroux, M., Mansat, V., Teixeira, M., Dumas, J.C. & Puel, J. (1993) Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrobial Agents and Chemotheraphy, 37, 12321237.
  • Wehmeier, A., Scharf, R.E., Fricke, S. & Schneider, W. (1989) Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis, 19, 251259.
  • Wehmeier, A., Fricke, S., Scharf, R.E. & Schneider, W. (1990) A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. European Journal of Haematology, 45, 191197.
  • Wehmeier, A., Daum, I., Jamin, H. & Schneider, W. (1991a) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Annals of Hematology, 63, 101106.
  • Wehmeier, A., Tschope, D., Esser, J., Menzel, C., Nieuwenhuis, H.K. & Schneider, W. (1991b) Circulating activated platelets in myeloproliferative disorders. Thrombosis Research, 61, 271278.
  • Weiss, H.J., Witte, L.D., Kaplan, K.L., Lages, B.A., Chernoff, A., Nossel, H.L., Goodman, D.S. & Baumgartner, H.R. (1979) Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood, 54, 12961319.
  • Willoughby, S. & Pearson, T.C. (1998) The use of aspirin in polycythaemia vera and primary thrombocythaemia. Blood Reviews, 12, 1222.
  • Wu, K.K. (1978) Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Annals of Internal Medicine, 88, 711.